BiotechTube

E7070 + Idarubicin + Cytarabine + Dexamethasone

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leukemia

Conditions

Leukemia

Trial Timeline

Feb 1, 2013 → Jun 7, 2017

NCT ID
NCT01692197

About E7070 + Idarubicin + Cytarabine + Dexamethasone

E7070 + Idarubicin + Cytarabine + Dexamethasone is a phase 2 stage product being developed by Eisai for Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01692197. Target conditions include Leukemia.

What happened to similar drugs?

20 of 20 similar drugs in Leukemia were approved

Approved (20) Terminated (1) Active (0)
✅micafungin + posaconazoleAstellas PharmaApproved
✅PirtobrutinibEli LillyApproved
✅PirtobrutinibEli LillyApproved
✅Pirtobrutinib + IdelalisibEli LillyApproved
✅Ibrutinib 420 mg + Ibrutinib 560 mgJohnson & JohnsonApproved
✅Venetoclax + AzacitidineAbbVieApproved
✅Venetoclax + Azacitidine + AzacitidineAbbVieApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01692197Phase 2Completed

Competing Products

20 competing products in Leukemia

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
11
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
42
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
39
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
PRGN-3006 T CellsPrecigenPhase 1
27
BisantreneRace OncologyPhase 2
29
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
15
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
25
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
ZN-d5Zentalis PharmaceuticalsPhase 1
19
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
26
Pirtobrutinib + IbrutinibEli LillyPhase 3
47
LY2523355Eli LillyPhase 1
21
TomivosertibeFFECTOR TherapeuticsPhase 1
23
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
40